Evaluation of Vaccination Coverage and Determinants of Success of the COVID-19 Vaccination Program Among Populations in Very Precarious Situations

COVID-19 Clinical Trial

— PREVAC  

Official title:

PREVAC: Evaluation of Vaccination Coverage and Determinants of Success of the COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05075941
• Other study ID #: 2021-A01960-41
• Status: Completed
• Start date: November 15, 2021
• Est. completion date: December 22, 2021

Study information

• Verified date: April 2023
• Source: Epicentre
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main objective of the study is to assess the level of vaccination coverage (VC) against COVID-19 among migrants, homeless and travelling community, according to their living conditions and housing.

The secondary objectives are :

• to compare the estimated level of vaccination coverage in the different sites and strata (emergency shelters/hotels, camps, workers' hostels, on the street) with the estimated level in the general population of the same territory obtained from the French Health Insurance data (SIVAC).

• identify the obstacles and leverage of vaccination (i.e. mobile team) according to living conditions and habitat (socio-demographic factors, personal health history, vaccine adherence, local health policies, etc.).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3811
• Est. completion date: December 22, 2021
• Est. primary completion date: December 22, 2021
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult (18 years and older)

• People considered as homeless (homeless, living in a camp or squat) or

• Living in adapted housing (migrant workers' hostel) or

• Housed in residences of the National System or

• Housed in a social residence such as a 115 hotel or a social housing centre

• Freely and voluntarily consenting to participate

Exclusion Criteria:

• Refusal to participate in the study (non-consent).

• Language barrier with no in-person or telephone translation available.

• Impossibility to give free and informed consent (comprehension barrier, cognitive and/or psychiatric and/or addictive disorders, external pressure from family and friends, persons under guardianship, etc.).

Related Conditions & MeSH terms

• COVID-19

Intervention

Other:
• Vaccination coverage
proportion of people declaring to have received at least one dose of vaccination against COVID-19 among target population

Locations

Country	Name	City	State
France	Marseille	Marseille
France	Paris	Paris

Sponsors (8)

Lead Sponsor	Collaborator
Epicentre	Agence Regionale de Sante d'Ile de France, CROIX ROUGE FRANCAISE, Institut de Recherche en Santé Publique, France, INTERLOGEMENT 93, Médecins du Monde, Medecins Sans Frontieres, Netherlands, OBSERVATOIRE DU SAMU SOCIAL

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vaccination coverage among COVID-19	Assess the proportion of people declaring to have received at least one dose of vaccination against COVID-19 among migrants, homeless and travelling community, according to their living conditions and housing	one month
Primary	Identify the most appropriate conditions for the use of vaccination against COVID-19	Promote interventions to encourage the use of COVID-19 vaccination	one month